Skip to main content
. 2018 Apr 11;15(6):9142–9150. doi: 10.3892/ol.2018.8463

Figure 4.

Figure 4.

Neutralizing IL-6 attenuates the action of BC-MSCs on inhibition of MCF-7 cells induced by cisplatin. (A) IL-6-neutralization antibody recovered cisplatin-induced apoptosis in MCF-7 cells incubated with BC-MSC-CM. **P<0.01, compared with the cisplatin group; #P<0.05, compared with the BC-MSC-CM group. (B) IL-6 neutralization antibody decreased the MCF-7 cell vitality. *P<0.05, compared with the cisplatin group; #P<0.05, compared with the BC-MSC-CM group. (C) Western blot analysis of protein levels of Bax, STAT3, p-STAT3, IL-6 in MCF-7 cells in response to the indicated treatment. IL-6, interleukin-6; BC-MSC, breast-cancer-derived mesenchymal-stem-cell-conditioned medium; p-STAT3, phosphorylated signal transducer and activator of transcription 3; Bax, B-cell lymphoma-associated X.